Information Provided By: 
Fly News Breaks for February 19, 2018
AZN
Feb 19, 2018 | 08:17 EDT
Deutsche Bank analyst Richard Parkes says FDA approval of Imfinzi for stage III unresectable lung cancer further de-risks AstraZeneca's lung cancer franchise. The analyst expects the Tagrisso/Imfinzi franchise to add over $4B in "incremental high margin sales" from lung cancer over the next four years. Although expected by investors, the approval comes one month sooner than anticipated, Parkes tells investors in a research note. AstraZeneca is the analyst's top pick in European pharma.
News For AZN From the Last 2 Days
AZN
Apr 23, 2024 | 11:16 EDT
Bearish flow noted in AstraZeneca with 3,362 puts trading, or 1.7x expected. Most active are 4/26 weekly 70 puts and May-24 70 calls, with total volume in those strikes near 3,600 contracts. The Put/Call Ratio is 1.72, while ATM IV is up nearly 2 points on the day. Earnings are expected on April 25th.
